SEARCH RESULT

Total Matching Records found : 288

Ranbaxy fined $500 m for flawed generics-Narayan Lakshman

-The Hindu Ranbaxy, one of India's largest pharmaceutical companies, has agreed to pay $500 million fines levied by U.S. authorities for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S. The deal struck on Monday, said to be the largest financial penalty against a generic drug company for violations of FDA standards, came...

More »

The Cost of Drugs: Beyond the Supreme Court Order -Sanjay Nagral

-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for affordable medicines in the country will actually be one only when there is a pro-patient slant to the...

More »

HIV, cancer patients seek access to affordable medicines-Aarti Dhar

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

More »

Finally, the patients prevail -Sarah Hiddleston

-The Hindu The Supreme Court has denied Novartis a patent for its anti-cancer drug Gleevec. This leaves the door open for Indian pharmaceutical companies to produce their own versions of the drug. Since these are sold at roughly one tenth of the patented brand price, for thousands of cancer patients it means the difference between medicine and no medicine at all. It is not just cancer patients that will benefit, but...

More »

EU, Australia, Canada may follow India’s Patent Law -Divya Rajagopal

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close